RecruitingPhase 2 / Phase 3NCT07581002
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
Sponsor: AbbVie
Duarte, CA · Tampa, FL · Atlanta, GA · +3 more sites